On August 12, 2026 Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, reported it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-288061),Form S-1MEF (File No. 333-288134), Form S-3 (File No. 333-284969) and Form S-3 (File No. 333-283983).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Separately, pursuant to a securities purchase agreement, the Company agreed to sell to certain purchasers in a private placement (the "PIPE") up to 861,708 unregistered shares of common stock (the "Shares") at a purchase price of $4.03 per share (or, at a purchaser’s election to comply with a 4.99% or 9.99% beneficial ownership limitation, pre-funded common stock purchase warrants (the "Pre-Funded Warrants") to purchase up to 861,708 shares in lieu of such shares), together with common stock purchase warrants (the "Common Warrants") to purchase up to 4,308,540 shares of common stock at an exercise price of $4.03 per share. The Pre-Funded Warrants will be exercisable immediately and will expire upon exercise in full, and the Common Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date (together, the "PIPE Warrants").

The aggregate gross proceeds from the transactions described herein are expected to total approximately $4.5 million, before deducting placement agent fees and expenses.

Roth Capital Partners, LLC is acting as the Company’s exclusive placement agent in connection with these transactions.

The transactions are expected to close on or about August 13, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transactions for working capital purposes.

The Inducement Warrants, the Shares, the Pre-Funded Warrants and the Common Warrants described above were offered in private placement transactions pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"), and Rule 506 promulgated thereunder, as applicable, and, along with the shares of common stock issuable upon exercise of the Inducement Warrants, the Pre-Funded Warrants and the Common Warrants, have not been registered under the 1933 Act and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the Shares and the shares of common stock issuable upon exercise of the Inducement Warrants, the Pre-Funded Warrants and the Common Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

(Press release, Aptevo Therapeutics, AUG 12, 2026, View Source [SID1234670023])

On August 12, 2026 Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial. The team remains focused on advancing our differentiated pemvidutide franchise in both MASH and AUD, each an area of unmet need with substantial future sales potential," said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. "We are also pleased to announce completion of enrollment in the RESTORE Phase 2 ALD trial. Our momentum positions Altimmune to deliver on our goals of bringing pemvidutide to patients with serious liver diseases and creating value for shareholders."

Key Highlights and Anticipated Milestones

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Pemvidutide was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) based on 24-week data from the IMPACT Phase 2b trial
In August 2026, the Company announced the initiation of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029
The PERFORMA trial is a Phase 3, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects with MASH

Alcohol Use Disorder (AUD)

In July 2026, the Company reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide in AUD
The RECLAIM trial evaluated the safety and efficacy of pemvidutide versus placebo in 100 patients with AUD over a 24-week treatment period
Pemvidutide achieved a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial
Important secondary endpoints were also met, including a 2-level reduction in WHO-risk drinking levels and zero heavy drinking days, both recognized by the FDA as registrational endpoints
A generally favorable safety and tolerability profile was observed in the trial
The Company plans to request an End-of-Phase 2 meeting with the FDA and engage with the European regulatory agencies to discuss a path forward in AUD
The FDA granted Fast Track designation to pemvidutide for the treatment of AUD

Alcohol-associated Liver Disease (ALD)

In July 2026, the Company completed patient enrollment in the RESTORE Phase 2 trial of pemvidutide in ALD
The RESTORE trial is a 48-week study evaluating the safety and efficacy of pemvidutide versus placebo in approximately 120 patients with liver disease due to excessive alcohol consumption
The trial enrolled patients with ALD and a history of chronic and heavy drinking at baseline
To support future regulatory discussions, the Company has amended the trial protocol to more fully evaluate the liver benefits pemvidutide may provide after one year of treatment in the ALD population
The primary endpoint, change from baseline in Liver Stiffness Measurement (LSM), will now be assessed hierarchically at Week 48 and then at Week 24
The secondary endpoints include changes in Enhanced Liver Fibrosis (ELF) score, alcohol consumption and body weight
The Company expects to report topline data in the second half of 2027

Corporate Updates

In April 2026, the Company completed an oversubscribed public offering of common stock, pre-funded warrants, and stock warrants, resulting in gross proceeds of $225.0 million
In June 2026, the Company announced plans to relocate its corporate headquarters to Morristown, New Jersey later in 2026

Financial Results for the Three Months Ended June 30, 2026

Altimmune reported cash, cash equivalents and investments totaling $519 million as of June 30, 2026
Research and development (R&D) expenses were $18.7 million for the three months ended June 30, 2026, compared to $17.2 million in the same period in 2025, with the increase driven primarily by the ongoing ALD trial as well as the startup costs for the PERFORMA Phase 3 trial in MASH, partially offset by the decrease in expenses related to completion of the IMPACT Phase 2b trial in MASH, which was ongoing in 2025. R&D expenses for the quarter ended June 30, 2026, included $11.6 million in direct costs related to pemvidutide development activities
General and administrative (G&A) expenses were $7.6 million for the three months ended June 30, 2026, compared to $5.7 million in the same period in 2025. The increase was driven primarily by an increase in professional services and compensation expenses in the second quarter of 2026
Interest income was $4.5 million for the three months ended June 30, 2026
Net loss for the three months ended June 30, 2026, was $22.8 million, or $0.12 net loss per share, compared to a net loss of $22.1 million, or $0.27 net loss per share, in the same period in 2025

Conference Call Information:
Date: August 12, 2026
Time: 8:30 a.m. Eastern Time
Webcast: To listen, the conference call will be webcast live on Altimmune’s Investor Relations (IR) website at View Source
Dial-in: To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call.

Following the conclusion of the call, the webcast will be available for replay on the IR page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

About Pemvidutide

Pemvidutide is an investigational novel peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In July 2026, the Company completed enrollment of the RESTORE Phase 2 trial in ALD.

(Press release, Altimmune, AUG 12, 2026, View Source [SID1234670022])

On August 12, 2026 Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), reported the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication, "Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial," reports the complete efficacy, safety and biomarker analyses from the study and details the statistical basis for the DKK1 biomarker finding. It is available online at View Source

The peer-reviewed analyses establish that the benefit of sirexatamab increases as a patient’s baseline plasma DKK1 level rises — a relationship confirmed by independent statistical approaches and reinforced by the observation that high DKK1 predicts poorer outcomes on standard of care alone. Together, these findings define DKK1-high mCRC as a biologically distinct population with high unmet need and provide the scientific foundation for a biomarker-selected Phase 3 trial. Additional information regarding the Company’s regulatory plans and strategic process for sirexatamab is included in the second quarter 2026 financial results announcement issued today by Cypherpunk Technologies Inc.

"In second-line colorectal cancer, we urgently need novel biomarkers that inform patients’ treatment options. The final data from the DeFianCe study show that baseline plasma DKK1 identifies patients with more aggressive disease, and it identifies the patients who benefit most from adding sirexatamab. Patients with high DKK1 do worse on standard of care, and they are the patients who gained the most in response and survival when sirexatamab was added," said Zev Wainberg, MD, Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program.

"Microsatellite-stable colorectal cancer remains one of the most difficult settings in gastrointestinal oncology, as patients whose disease progresses after first-line therapy have quite limited options. We need new liquid biopsy biomarkers that tell us effectively which patients will benefit from which therapy. These data support the utility of baseline plasma DKK1 as a liquid biomarker for improving response rates and survival with sirexatamab, making a compelling case for a biomarker-selected Phase 3 registrational trial," said Markus Moehler, MD, PhD, Head of GI Oncology, Senior Physician Gastroenterology & Endosonography Head at the Mainz University Clinic.

Key Findings from the Publication
DeFianCe (NCT05480306) was a two-part, randomized, open-label, multicenter Phase 2 study. Part B randomized 188 patients 1:1 to sirexatamab plus FOLFIRI or mFOLFOX6 and bevacizumab (Sirexatamab Arm) or to chemotherapy and bevacizumab alone (Control Arm). The primary endpoint was investigator-assessed progression-free survival (PFS); secondary endpoints included objective response rate (ORR) and overall survival (OS). Baseline plasma DKK1 was a prespecified candidate biomarker.

Sirexatamab benefit increased as baseline plasma DKK1 rose

Three independent analyses — a continuous treatment-by-DKK1 interaction model, a permutation-tested Biomarker Adaptive Threshold (BAT) analysis, and median- and upper-quartile subgroup analyses — converged on the same conclusion: benefit rises with baseline plasma DKK1.
The treatment-by-DKK1 interaction was statistically significant for both PFS (p=0.0129) and OS (p=0.0027), with DKK1 modeled as a continuous variable.
The BAT analysis with permutation testing reached the same conclusion (PFS p=0.018; OS p<0.001), and the data-driven cut points aligned with the median and upper quartile of baseline plasma DKK1.
DKK1-high patients above the median (n=88)

ORR was 38.0% in the Sirexatamab Arm compared with 23.7% in the Control Arm.
Median PFS was 9.0 months versus 7.1 months; HR 0.61 (95% CI, 0.37–1.00); p=0.0255.
Median OS was not reached versus 14.4 months; HR 0.42 (95% CI, 0.19–0.91); p=0.0118.
DKK1-high patients in the upper quartile (n=44)

ORR was 44.0% in the Sirexatamab Arm compared with 15.8% in the Control Arm; p=0.0149.
Median PFS was 9.4 months versus 5.9 months; HR 0.46 (95% CI, 0.22–0.96); p=0.0168.
Median OS was not reached versus 9.5 months; HR 0.17 (95% CI, 0.05–0.53); p<0.001.
Higher baseline DKK1 was also prognostic of poor outcome

In the Control Arm, median OS declined as DKK1 rose — not reached in the overall population, 14.4 months above the median, and 9.5 months in the upper quartile — consistent with published evidence linking elevated DKK1 to more aggressive disease.
DKK1-high patients therefore represent a population with both poor prognosis on standard therapy and the greatest observed benefit from sirexatamab.
Plasma DKK1 is a practical, blood-based biomarker

Baseline plasma DKK1 was detectable in 100% of patients across an approximately eight-fold dynamic range.
Levels were concordant across two orthogonal platforms — an aptamer-based SomaScan assay and an antibody-based Meso Scale Discovery (MSD) assay (Spearman r=0.77).
Tumoral DKK1 mRNA expression was low in most tissue samples, reinforcing that plasma — not tissue — reflects the systemic DKK1 burden relevant to colorectal cancer biology, and supporting a blood-based patient-selection test.
Results in the overall intent-to-treat (ITT) population

The prespecified primary endpoint of PFS in the ITT population was not met. Median PFS was 9.2 months in the Sirexatamab Arm versus 8.3 months in the Control Arm; HR 0.84 (95% CI, 0.58–1.21). ORR was 35.1% versus 26.6%, and median OS was not reached in either arm; HR 0.83 (95% CI, 0.46–1.48).
The final analysis included 119 investigator-assessed PFS events against the 145 events planned, leaving the ITT analysis underpowered in a biologically heterogeneous population.
Safety

Sirexatamab in combination with chemotherapy and bevacizumab was generally well tolerated. Grade 3 or higher treatment-emergent adverse events (TEAEs) occurred in 59.3% of patients in the Sirexatamab Arm compared with 67.0% in the Control Arm, and serious TEAEs were comparable between arms (19.8% versus 19.3%).
TEAEs leading to discontinuation of sirexatamab occurred in 4.4% of patients, indicating that adding sirexatamab did not meaningfully change the tolerability of standard of care.
About Sirexatamab (DKN-01)
Sirexatamab (DKN-01) is a humanized monoclonal antibody that binds and neutralizes Dickkopf-related protein 1 (DKK1), a secreted modulator of Wnt signaling associated with more aggressive disease, immune suppression, angiogenesis and poorer outcomes in colorectal and other cancers. In May 2026, the FDA granted Fast Track designation to sirexatamab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab for the treatment of patients with DKK1-high metastatic colorectal cancer whose disease has progressed following one prior systemic therapy.

(Press release, Leap Therapeutics, AUG 12, 2026, View Source [SID1234670021])

On August 12, 2026 ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our FURVENT and ALPACCA global pivotal trials have the potential to establish firmonertinib as a first-line treatment option for uncommon EGFR mutations in non-small cell lung cancer (NSCLC), addressing a significant unmet need for patients who remain underserved by current therapies," said Bing Yao, CEO of ArriVent. "In parallel, we continue to build a differentiated ADC portfolio, with ARR-217 advancing into dose optimization and ARR-002 advancing in clinical development. We look forward to presenting pivotal topline data from our global FURVENT study for firmonertinib and initial Phase 1 data for ARR-217."

Second Quarter 2026 and Recent Highlights

Firmonertinib

· Phase 3 study supported by crystal structure data presented at AACR (Free AACR Whitepaper). Ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant NSCLC supported by preclinical data for EGFR inhibitor firmonertinib showcased high resolution crystal structure data at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting.

Pipeline

· Initiated Phase 1b Dose Optimization of ADC lead ARR-217 (MRG007). ArriVent has initiated Phase 1b dose optimization for ARR-217, a CDH17 targeted ADC, in patients with gastrointestinal malignancies in partnership with Lepu Biopharma Co., Ltd.

· Clinically advancing ARR-002 in ovarian and endometrial cancer. ArriVent advancing ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, into the clinic through a first-in-human study evaluating safety, dosing, and early signals of efficacy in patients with ovarian and endometrial cancers following Investigational New Drug (IND) clearance from the Food and Drug Administration (FDA) in May 2026.

· Greater China license agreement with Allist for ARR-002. ArriVent entered into an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. (Allist) to develop and commercialize ARR-002 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan, with all other rights retained by ArriVent.

Upcoming Milestones

· Firmonertinib pivotal EGFR exon 20 insertion data. Top-line data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is anticipated in 2H 2026.

· Initial Phase 1 data for ARR-217. Initial Phase 1 dose escalation data for ARR-217 planned to be presented at a future medical conference.

· Dosing of first patient with ARR-002. Dosing of first patient with ARR-002 in a Phase 1 trial expected in the third quarter of 2026.

2026 Financial Results

· As of June 30, 2026, the Company had cash and investments of $373.1 million, which is expected to fund operations into 2028.

· Net cash used in operations was $81.5 million and $94.1 million for the six months ended June 30, 2026 and 2025, respectively.

· Research and development expenses were $80.0 million and $89.0 million for the six months ended June 30, 2026 and 2025, respectively.

· General and administrative expenses were $18.8 million and $11.4 million for the six months ended June 30, 2026 and 2025, respectively.

· Net loss was $93.2 million and $95.8 million for the six months ended June 30, 2026 and 2025, respectively.

(Press release, ArriVent Biopharma, AUG 12, 2026, View Source [SID1234670019])

On August 12, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Offering"), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units ("Units") at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering from $1,500,000 to up to $2,000,000 and extending the Offering by 30 days to September 10, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Unit consists of one common share of the Company (each a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant entitles the holder to acquire one additional Share at an exercise price of $0.20 per Share for a period of 24 months from the date of issue.

In connection with the First Tranche, the Company paid aggregate cash finder’s fees of $85,315 and issued an aggregate of 853,150 finder’s units (the "Finder’s Units") to arm’s length finders. Each Finder’s Unit entitles the holder to acquire one Share at a price of $0.10 per Share and one-half of one share purchase warrant, with each whole warrant exercisable to acquire one additional Share at a price of $0.20 per Share, in each case for a period of 24 months from the date of issue.

Proceeds of the Offering will be used to advance Rakovina’s pipeline, with a primary focus on in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program and continued AI-driven lead optimization through the Company’s collaboration with Variational AI. Funds will also support advancement of the kt-3000 LNP formulation program, ongoing kt-2000AI compound development, and general working capital.

"We are encouraged by the strong support we’ve received from both existing shareholders and new investors," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. "Increasing the size of this financing positions us to build on our scientific momentum and execute on important milestones ahead as we work to deliver transformational therapies for patients. In addition, we are enhancing our relationships with the AI companies that help us accelerate drug discovery and development and seeking non-dilutive financing from government and industry sources."

Insider Participation

Insiders of the Company purchased an aggregate of 1,900,000 Units in the First Tranche for aggregate gross proceeds of $190,000. Participating insiders were Kim Oishi, Chief Executive Officer and Director of the Company, whose subscription was made through First Growth Equity Partners Inc., and David Kideckel, Chief Financial Officer and Director of the Company. The Units issued to insiders are subject to a four months and one day hold period pursuant to applicable policies of the TSX Venture Exchange (the "TSXV").

The issuance of Units to insiders is considered a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a) in respect of such insider participation, as the fair market value of the transaction, insofar as it involves interested parties, does not exceed 25% of the Company’s market capitalization.

The Offering remains subject to customary closing conditions, including approval by the TSXV. The Company expects to close one or more additional tranches of the Offering.

The Units were issued pursuant to exemptions from the prospectus requirements under Canadian securities laws under National Instrument 45-106 – Prospectus Exemptions. All securities issued under the Offering are subject to a hold period of four months and one day from the date of closing, in addition to any other restrictions under applicable law.

(Press release, Rakovina Therapeutics, AUG 12, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-closing-of-first-tranche-upsize-and-extension-of-non-brokered-private-placement [SID1234670016])